You can buy Prasedx at the lowest price in the online pharmacy Nextgen.ooo . Pralsetinib, like the previously approved selpercatinib, is a kinase inhibitor with increased specificity for the RET receptor tyrosine kinase (RTK) compared to other classes of RTKs. Increased expression of the RET oncogene (rearranged during transfection) is a hallmark of many cancers, including non-small cell lung cancer.
 
While multikinase inhibitors including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with significant toxicity. Pralsetinib (BLU-667) and Selpercatinib (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers. While the Phase 1/2 pralsetinib study called ARROW (NCT03037385) is still ongoing, on September 4, 2020, pralsetinib received accelerated approval from the FDA for the treatment of RET fusion-positive metastatic non-small cell lung cancer.